ENUM .0068 $67M REVENUES Potential for future development milestones of up to an aggregate of $37.8 million and net sales
milestone payments of up to an aggregate of $67.5 million, each upon achievement of specified
targets.
– Potential for royalties in the low-to-lower middle single digits as a percentage of net sales,
depending on the amount of net sales in applicable years.
• Pieris has an option until May 31, 2017 to license specified Enumeral patent rights and know-how
covering two additional undisclosed antibody programs on the same terms and conditions as for the
388D4 antibody. Pieris will pay Enumeral additional undisclosed license fees in the event that Pieris
exercises one or both of these options.
• Enumeral can continue to develop or partner the 388D4 PD-1 program, as well as the other antibody
programs subject to the option described above, provided that Enumeral has agreed not to conduct,
or assist third parties in conducting, activities that involve an antibody licensed under the Pieris
License and Transfer Agreement fused with or linked to one or more Anticalin proteins in the field of
oncology.
26
OTCQB:
Everything I say is in my opinion, do your own DD and make your decision wisely! Don't spend more then you can afford to lose!
